Picture the moment a buyer's team opens a data room for a specialty chemical company. The financials are tidy. Revenue is recurring. The end markets are defensible. Then someone asks about the formulation for the product that generates 40% of revenue, and the answer comes back: it's in Dave's notebooks. Dave has been here 31 years. Dave is 64.
That moment, which plays out more often than anyone in this market will admit, is now a pricing event.
Technology readiness has become a line item in specialty chemicals M&A. Not a talking point for the management presentation. Not a nice-to-have that gets addressed in a 100-day plan. A quantified input that sophisticated buyers use to adjust the number they put on the table before they sign a letter of intent. The due diligence checklist that once ran through financials, customer concentration, and environmental liability now has a dedicated technology workstream. The question it's trying to answer is whether the knowledge inside the business lives in people who will eventually leave, or in systems that will not.
At HarborWind Partners, that question is central to how we think about value. We acquire specialty chemical businesses, and the work we do after closing is built around a simple principle: technology should capture what your best people know and make it repeatable, permanent, and scalable. The experienced chemist who has been adjusting batch parameters by feel for 25 years doesn't lose their job. Their expertise gets encoded into a system that makes every shift as good as their best shift. They move on to the problems that require human judgment, creativity, and experience. The mundane and the repeatable get handled by tools that don't forget, don't fatigue, and don't retire.
That philosophy shapes how we read a business when we look at it. We see what a company is today, and we see what it could become with the right infrastructure in place. Increasingly, so does every serious buyer in this market.
Here is what the specialty chemicals M&A market looks like right now: who is buying, what they're paying, what they're rewarding, and what is catching sellers off guard.
"The notebook that Dave has been keeping for 31 years is, legally speaking, a depreciating asset."
In 2025, the specialty chemicals M&A market did something unusual. Deal volume fell sharply, and prices went up anyway.
According to Capstone Partners' July 2025 chemicals M&A report, transaction volume dropped 27.6% year-over-year, from 87 deals to 63. At the same time, average deal values rose 4.5%. The overall average multiple landed at 9.0x EBITDA, or 9.6x when distressed divestitures are pulled out of the calculation. For private equity transactions involving higher-quality assets in North America and Europe, the median was 12.2x.
That combination, fewer deals at higher prices, sounds contradictory until you look at what actually happened. The businesses that are transacting, the ones with clean books, documented IP, and strong end-market positioning, are clearing at prices the market hasn't seen since the peak years. The businesses that aren't those things are sitting. The decline in volume isn't a sign of a weak market. It's a sign of a more selective one.
The broader lower middle market confirmed the pattern. Diamond Capital Advisors reported a Q3 2025 rebound to 9.4x for LMM transactions across sectors, consistent with the specialty chemicals data. And when Axial surveyed dealmakers heading into 2026, 70.5% said they were optimistic about the year ahead.
End-market exposure explains much of the spread between the deals that clear well and the deals that don't. Companies supplying pharmaceutical manufacturers, semiconductor fabs, or defense contractors are regularly trading above 10x, sometimes well above it. The chemistry is defensible, the customers are sticky, and the switching costs are real. Companies with commodity-adjacent exposure live in a different world. The acquisition of a Goodyear polymer unit in 2025 cleared at 5.0x, a figure that captures what happens when chemistry gets commoditized and pricing power erodes.
The survivorship bias in that 9.6x average number is worth sitting with. That multiple reflects the businesses that actually sold. The ones that didn't, the ones with owner dependence baked into every customer relationship, or formulation data scattered across a decade of notebooks, or an ERP system that hasn't been touched since the Bush administration, those businesses didn't transact. They are not in the average. Which means the real bifurcation in this market is sharper than the headline numbers suggest.
"The businesses that are actually selling are clearing at 9.6 times earnings. The rest are sitting."
For a well-prepared seller of a quality specialty chemical business, there is a counterintuitive opportunity embedded in all of this. Because volume has declined, that seller faces less competition for serious buyer attention than at any point in the past five years. The buyers who are active are hungry. The businesses they're competing for are fewer. That is a good position to be in, if you've done the work to earn it.
Most founders who begin thinking about an exit picture the obvious buyer. A competitor in their space. A larger chemical company looking to fill a product gap. A customer who wants to own the supply chain. That mental model isn't wrong, but it is incomplete, and the incompleteness is expensive.
According to Capstone Partners, private equity accounted for 47.6% of all specialty chemicals transactions in 2025. Strategic buyers represented the rest. Within the PE share, platform acquisitions reached 19.5% of deals, the highest level since 2018. PE firms are not drifting into specialty chemicals. They are building there intentionally, particularly in CASE (coatings, adhesives, sealants, and elastomers), pharma ingredients, and electronic chemicals. They are not passive holders waiting for an exit. They are active acquirers looking for businesses with defensible IP, recurring customer relationships, and room to grow through add-on acquisitions. The median multiple they paid for higher-quality assets in 2025 was 12.2x.
But the multiple is only part of the picture. The more interesting question is who's writing the check.
Axial's 2025 State of the Lower Middle Market report identified independent sponsors as the number-one buyer type by deal count in the broader lower middle market, representing 27% of transaction volume. There are now more than 1,500 active independent sponsors operating in the US, a figure that has roughly doubled in five years according to Methodica Capital. Independent sponsors raise deal-specific capital from family offices, high-net-worth investors, and institutional limited partners rather than managing committed funds. They move at the speed of an individual decision-maker rather than an investment committee. They often bring operating expertise alongside capital, and they are frequently more flexible on deal structure than traditional PE firms because they don't have a fund clock running.
The information gap between what sellers assume about the buyer market and what is actually true in that market is one of the most expensive blind spots in any sale process. A specialty chemical company owner who runs a narrow process targeting only strategic acquirers has made a decision, probably without realizing it, to reduce the competitive tension in their deal. The buyers most likely to pay a premium for a business with strong formulation IP, clean operations, and a real technology story are often the buyers that sellers don't think to call.
"The buyers most likely to pay a premium are often the buyers that sellers don't think to call."
The answer is yes, and the premium is larger than most sellers expect.
McKinsey's research on digital transformation in the chemicals sector found that companies that successfully execute it capture between 8.5 and 16 EBITDA percentage points of improvement. In a business running at $5M in EBITDA, that range represents a meaningful absolute dollar figure before multiple expansion enters the conversation. The same research found that digitally rewired companies see two to three turns of multiple expansion relative to peers. On a 9.6x baseline, that is the difference between a 9.6x deal and a 12.0x deal. On a $5M EBITDA business, that gap is $12M.
RSM, one of the more active advisors in mid-market M&A, put it plainly in their 2025 chemicals M&A analysis: "Fragmented, disconnected ERP environments can create avoidable deal friction, valuation pressure and timeline risk." That is the translation from deal advisory language into plain English: technology debt shows up in the offer price. It is not a problem you negotiate away after closing. It is a problem that gets priced in before you get there.
Bain & Company runs dedicated technology due diligence workstreams in their deal evaluations, a practice that has become standard at institutional PE firms. The 2026 Deloitte Manufacturing AI Adoption report found that 51% of US manufacturers now deploy AI in daily operations. The buyer sitting across the table from a specialty chemical owner has an increasingly specific view of what technology-enabled operations look like, and what a technology gap costs to close. They have seen both.
So what does this actually look like inside a specialty chemical business? Our analysis of AI in specialty chemicals covers the specific applications, the implementation economics, and what actually delivers ROI versus what is still hype.
Formulation management. The most common form of IP risk in a specialty chemicals sale is formulation data that lives in a chemist's notebooks, personal files, or memory rather than in a managed digital system. CAS research has found that 80% of scientific data becomes unavailable after 20 years, through retirement, turnover, and inadequate documentation practices. A buyer who has seen this problem before will discount for it. Not because they can't solve it, but because solving it takes time and money, and they know it. Companies with documented, digitized formulation libraries are consistently valued at roughly twice the level of comparable businesses without that documentation, according to deal practitioner experience. The notebook that Dave has been keeping for 31 years is, legally speaking, a depreciating asset.
Batch optimization. TrendMiner, an industrial analytics platform deployed across specialty chemical sites, published data showing that removing 30 minutes from a nine-hour batch cycle generates approximately $1M per year in throughput value for a typical specialty chemical operation. Process analytics tools identify those opportunities by analyzing historical batch data and flagging the parameters that correlate with faster cycle times and better yields. Experienced process engineers still make the judgment calls. The system finds the patterns that human review alone would miss, in the data that has always been there but was never systematically examined.
Quality control. Computer vision systems deployed on production lines are detecting defects in real time, with batch rejection rates falling by more than 70% at sites that have implemented them. The quality teams at those sites are not being replaced. They are being redeployed from manual inspection tasks to analytical work: root cause analysis, supplier qualification, customer complaint resolution. That is a better use of people who spent years developing expertise in how things go wrong.
Predictive maintenance. Unplanned downtime in chemical manufacturing is expensive in ways that are easy to underestimate until you've seen the number. BASF has reported an average cost per unplanned maintenance incident of $86,000. Before anyone picks up a wrench, before any parts are ordered. SABIC's figure is $107,000 per incident. KCF Technologies, which deploys vibration-based predictive maintenance across industrial sites, documented $19.2M in savings across more than 40 chemical manufacturing sites. Predictive maintenance doesn't replace the maintenance technician who has learned to hear a failing bearing before the gauges show anything. It catches the failures that human observation misses between walkthroughs.
This is the work HarborWind does inside the companies we acquire. We implement digital tools that capture what your best people know, make that knowledge permanent and scalable, and free them for the work that actually requires a human. The goal is not to make technology the story. The goal is to make the business more durable, more valuable, and more resilient than it was before.
One important caveat on the data: no published dataset directly measures the technology multiple premium in actual lower middle market chemical deal data with statistical precision. McKinsey's two-to-three turn figure comes from a consulting study of digitally transformed companies, not a controlled transaction dataset. That limitation is worth acknowledging. It also cuts in a useful direction. The sellers who build a compelling, documented technology story today are operating in relatively uncrowded territory. Buyers have a thesis and limited data to test it against. A well-documented technology story is more powerful right now, not less, precisely because the counterargument hasn't been assembled yet.
Environmental due diligence has always been part of a chemical company transaction. What has changed in the past two years is the specific risk surface that serious buyers are focused on, and the regulatory framework that gives that risk real consequences.
PFAS is the clearest example of how quickly the landscape can shift. Per- and polyfluoroalkyl substances are a broad class of synthetic chemicals used across industrial and consumer applications for decades. Most specialty chemical companies that used them did so routinely, often without tracking their presence specifically. In April 2024, the EPA designated two PFAS compounds, PFOA and PFOS, as hazardous substances under CERCLA. That designation carries consequences that extend well beyond future product restrictions.
CERCLA imposes strict liability. It is joint and several across all potentially responsible parties. A company can be held responsible for remediation costs regardless of fault, regardless of when the contamination occurred, regardless of whether it caused the problem or simply existed on a site that had the problem. For specialty chemical companies, PFAS exposure can take several forms: direct use in formulations, discharge into wastewater streams over many years, disposal at third-party sites now under investigation. In some transactions, buyers have discovered post-closing that product lines considered core to the business were either in violation of TSCA or facing near-term bans that effectively zeroed out their value.
Remediation costs in PFAS cases have exceeded total enterprise value. That is not a theoretical risk. It has happened. It has happened in transactions where buyers did not conduct proactive testing before closing, and where sellers either didn't know what they had or chose not to surface it. Neither outcome is good for anyone involved.
The regulatory framework tightened further in December 2024, when the EPA and OSHA formalized a memorandum of understanding for coordinated enforcement under TSCA Section 6. The practical effect is that enforcement actions are more likely to be simultaneous across agencies rather than sequential, which reduces a company's ability to address one regulatory issue at a time before the next one arrives.
The buyer community has absorbed this. ESG and environmental diligence is now standard in chemical M&A at any serious institutional acquirer. Buyers who find PFAS exposure that sellers haven't disclosed or quantified respond predictably: the deal reprices dramatically, or it doesn't close.
The structural tension this creates runs directly through deal negotiations. Buyers prefer asset purchases in chemical transactions because asset structures allow them to leave unknown environmental liabilities behind in a shell entity. Sellers prefer stock sales for the tax treatment. A seller who hasn't audited their formulations and operations for PFAS exposure before going to market has very limited leverage in that negotiation. A seller who has done the work, knows exactly what they have, and can present a clean bill of health has a significantly stronger hand.
Most mid-market specialty chemical owners have never conducted a proactive PFAS audit. The cost of that audit is modest relative to deal transaction costs. Running it before a buyer does is one of the highest-return preparation steps available to a seller in today's market. The alternative is finding out what you have at a moment when the buyer already knows.
What EBITDA multiple should I expect for my specialty chemical company?
The current range runs from 5x at the low end to 12x or higher for businesses with differentiated IP, strong end-market exposure, and clean operations. The 2025 average excluding distressed divestitures was 9.6x. Companies serving pharmaceutical, semiconductor, or defense end markets consistently trade above 10x. The factors most likely to compress a multiple below the market average are customer concentration, owner dependence on day-to-day operations, and environmental liability. Each of those is a problem that benefits from being addressed before a sale process begins rather than during one.
How long does it take to sell a specialty chemical company?
A well-prepared sale takes 12 to 18 months from the decision to sell to a closed transaction. The preparation work, which includes cleaning up financials, documenting processes, reducing owner dependence, and addressing customer concentration, ideally begins 12 to 36 months before engaging buyers. Sellers who start that work early consistently achieve better outcomes than sellers who start it after the process is already running. The Founder’s Guide to Selling a Manufacturing Business walks through what that preparation looks like in practice. A buyer who finds preparation work still in progress during diligence will wonder what else is still in progress.
Do private equity firms buy specialty chemical companies?
Yes. Private equity accounted for 47.6% of all specialty chemicals transactions in 2025. PE firms are actively building platforms in the sector, particularly in CASE chemistry, pharma ingredients, and electronic chemicals. Platform acquisitions as a share of PE deal activity hit their highest level since 2018, which means PE buyers are looking for businesses they can use as foundations to acquire around, not just standalone investments to hold and exit.
Does my technology infrastructure affect my company's sale price?
Increasingly, yes. Buyers now run technology due diligence alongside financial and environmental diligence. Companies with digitized formulation libraries, modern ERP systems, and data-driven process operations command measurably higher multiples according to McKinsey's research on digital transformation in chemicals. Fragmented or manual systems create deal friction, extend timelines, and give buyers a documented basis for valuation adjustments. The gap between what a technology-ready business and a technology-lagging business clear for, in this market, is real and it is widening.
What is PFAS and why does it matter for chemical company M&A?
Per- and polyfluoroalkyl substances are a class of synthetic chemicals that the EPA designated as hazardous substances under CERCLA in 2024. Specialty chemical companies with PFAS in their formulations, waste streams, or site histories face potential product bans, remediation liability, and significant deal complications. CERCLA's strict liability standard means that historical, inadvertent PFAS exposure can create financial obligations that survive a transaction and attach to the buyer. Serious acquirers test for this. Sellers who know what they have going in are in a far better position than sellers who find out during diligence.
Is now a good time to sell a specialty chemical company?
For prepared sellers, the data suggests it is. Deal volume has declined, which means a well-prepared business faces less competition for serious buyer attention than at any point in the past five years. Multiples for quality assets remain strong. Tariff protections enacted in 2025 have improved the competitive position of domestic specialty chemical producers relative to imports. The combination of fewer quality businesses on the market and an active, well-capitalized buyer pool creates favorable conditions for sellers who have done the work. The market is not waiting for the right time. It is waiting for the right businesses.
The specialty chemicals M&A market in 2025 and into 2026 is rewarding a specific kind of seller. Not the largest. Not the oldest. Not the one with the most revenue. The one who has invested in technology infrastructure, documented their IP, maintained a clean regulatory position, and built an operation that can run without them in the middle of every decision.
Those outcomes are not accidental. They are the result of work done years before a sale. A 10x multiple does not go to a company that hopes its processes are well-documented. It goes to the company that can demonstrate it in a data room, with receipts. For owners in adjacent sectors, the same dynamics apply: see our analysis of the niche manufacturing M&A market.
HarborWind Partners acquires founder-led specialty chemical businesses with $2.5M–$12M in EBITDA. We implement digital tools and operational systems that make these companies more valuable, more resilient, and more durable. We bring technology and operating depth to leadership teams that want to take their businesses further. And we hold for the long term, because compounding takes time.
Buy. Build. Compound.